Clik here to view.
Nucleix研发的Lung EpiCheck®液体活检，可检出高危吸烟者中85%的早期肺癌，该研究已发表于《欧洲呼吸杂志》。
圣迭戈与雷霍沃特，以色列 Nucleix，以色列一家对疾病进行早期检测从而彻底改变癌症治疗的液体活检公司，今日宣布在《欧洲呼吸杂志》最新论文中，该公司所研发的Lung EpiCheck®检测，可依据吸烟史在肺癌高危个体中检验出85%的早期肺癌。该论文已发表在《欧洲呼吸杂志》(ERJ)印刷版之前的在线版中，标题为“Lung...
View ArticleClik here to view.
Prokarium Closes $21M Series B Financing Round and Strengthens Board
LONDON Prokarium, a privately-held biotechnology company developing novel immunotherapies and vaccines based on its engineered microbial platform, today announced the closing of a Series B...
View ArticleClik here to view.
联拓生物宣布获得Infigratinib在中国大陆开展治疗针对具有FGFR2基因融合的局部晚期或转移性不可切除胆管癌患者的3期PROOF临床试验批件
上海和普林斯顿（新泽西州） (美国商业资讯) — 联拓生物，一家专注于为中国和亚洲主要市场的患者带来颠覆性药物的生物制药公司，今日宣布已获得中国国家药品监督管理局（NMPA）药品审评中心（CDE）关于Infigratinib的3期PROOF临床试验批件。Infigratinib是一种潜在的用于治疗伴有FGFR2基因融合的局部晚期或转移性不可切除胆管癌患者的一线治疗方式。...
View ArticleClik here to view.
武田2020财年上半年业绩展示出其产品组合的韧性；确认全年管理层指引，上调对自由现金流、列报营业利润和列报每股盈利的预测
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited) (TSE:4502/NYSE:TAK)（“武田”）今天公布其2020财年上半年（截至2020年9月30日期间）的财务业绩。 武田总裁兼首席执行官CHRISTOPHE WEBER评论道：...
View ArticleClik here to view.
Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present 22 company-sponsored abstracts at the 62nd American...
View ArticleClik here to view.
BeiGene Reports Third Quarter 2020 Financial Results
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today...
View ArticleClik here to view.
GE Healthcare, GenesisCare Partner to Tackle Two Biggest Health Burdens...
CHICAGO & SYDNEY GE Healthcare, the leading global provider of advanced medical imaging, and GenesisCare, a leading provider of integrated cancer care globally and cardiovascular care in...
View ArticleClik here to view.
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License...
HEMEL HEMPSTEAD, England & BEIJING, China, & CAMBRIDGE, Mass. EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Application...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Presents Preclinical Data at SITC 2020 Demonstrating...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced a...
View ArticleClik here to view.
HitGen Licenses Its Trk/ROS1 Inhibitor HG030 to Baiyunshan for Development...
CHENGDU, China HitGen Inc. (HitGen, 688222.SH) announces it has entered into a collaboration and licensing agreement with Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd (Baiyunshan,...
View ArticleClik here to view.
Prestige Biopharma and Teva Israel Announce License and Supply Agreement to...
SINGAPORE Prestige BioPharma Ltd. and Abic Marketing Ltd. (operates under the brand of Teva Israel, hereinafter “Teva Israel”), a subsidiary of Teva Pharmaceutical Industries Ltd. announced today...
View ArticleClik here to view.
武田肿瘤部在美国血液学会(ASH)第62届年会上展示其在血癌领域的领导地位
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited,...
View ArticleClik here to view.
武田薬品のオンコロジー部門が第62回米国血液学会（ASH）年次総会で血液がん治療におけるリーダーシップを示す
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Taiho and Lung Therapeutics Enter Into an Exclusive License Agreement in...
TOKYO & AUSTIN, Texas Taiho Pharmaceutical Co., Ltd, (“Taiho”) and Lung Therapeutics, Inc. (“Lung Tx”) announced today an exclusive license agreement of LTI-01, a recombinant human single-chain...
View ArticleClik here to view.
Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product
SYDNEY Australian clinical-stage drug development company Noxopharm (ASX: NOX) is pleased to announce it has joined with Bristol Myers Squibb (NYSE: BMY) in an Australian pilot study investigating...
View ArticleClik here to view.
Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it will create a new Oncology Business Unit, effective April 1, 2021,...
View ArticleClik here to view.
PierianDx and Bench International Announce the Appointment of Mark McDonough...
ST. LOUIS & SAN DIEGO PierianDx, the leading clinical genomics informatics company, and Bench International, a leading global executive search firm, jointly announce the appointment of Mark...
View ArticleClik here to view.
MedTech Innovator Names X-ZELL as 2020 Asia Pacific Final Competition Winner
LOS ANGELES & SINGAPORE MedTech Innovator, the largest accelerator of medical devices in the world, in partnership with Asia Pacific Medical Technology Association (APACMed), the first and only...
View ArticleClik here to view.
PierianDxとベンチ・インターナショナルがマーク・マクドナーを新たな最高経営責任者（CEO）に任命したと発表
セントルイス & サンディエゴ （ビジネスワイヤ） —...
View ArticleClik here to view.
PierianDx和Bench International宣布任命Mark McDonough为新的首席执行官
圣路易斯和旧金山 (美国商业资讯)–领先的临床基因组学信息公司PierianDx和全球领先的猎头公司Bench International共同宣布任命Mark...
View Article